CTI BioPharma Corp

NASDAQ:CTIC   11:33:47 AM EDT
2.60
-0.04 (-1.52%)
Products, Regulatory

Cti Biopharma Announces Topline Data From Final Analysis Of The Pre-Vent Clinical Trial Evaluating Pacritinib As A Treatment For Severe Covid-19

Published: 10/01/2021 20:22 GMT
CTI BioPharma Corp (CTIC) - Cti Biopharma Announces Topline Data From Final Analysis of the Pre-vent Clinical Trial Evaluating Pacritinib As a Treatment for Severe Covid-19.
Cti Biopharma Corp - Pre-vent Amended to a Phase 2 Study Due to Shifting Covid-19 Treatment Landscape.
Cti Biopharma - Pre-vent Did Not Achieve Pre-defined Statistical Significance for Primary Endpoint.
Cti Biopharma Corp - Have Decided Not to Pursue Further Development of Pacritinib for Treatment of Severe Covid-19.
Cti Biopharma - Will Continue to Focus Efforts on Launch Preparedness for Pacritinib in Myelofibrosis.